ATE307815T1 - Substituierte 2-pyrimidinyl-6,7,8,9- tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7- pyrimidinyl-2,3-dihydroimidazo(1,2-a)pyrimidin- 5(1h)onderivate gegen neurodegenerative erkrankungen - Google Patents

Substituierte 2-pyrimidinyl-6,7,8,9- tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7- pyrimidinyl-2,3-dihydroimidazo(1,2-a)pyrimidin- 5(1h)onderivate gegen neurodegenerative erkrankungen

Info

Publication number
ATE307815T1
ATE307815T1 AT02779461T AT02779461T ATE307815T1 AT E307815 T1 ATE307815 T1 AT E307815T1 AT 02779461 T AT02779461 T AT 02779461T AT 02779461 T AT02779461 T AT 02779461T AT E307815 T1 ATE307815 T1 AT E307815T1
Authority
AT
Austria
Prior art keywords
pyrimidinyl
pyrimidine
onderivates
tetrahydropyrimido
dihydroimidazo
Prior art date
Application number
AT02779461T
Other languages
English (en)
Inventor
Thierry Gallet
Patrick Lardenois
Alistair Lochead
Severine Marguerie
Alain Nedelec
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01402431A external-priority patent/EP1295884A1/de
Priority claimed from EP02290488A external-priority patent/EP1340760A1/de
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE307815T1 publication Critical patent/ATE307815T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
AT02779461T 2001-09-21 2002-09-19 Substituierte 2-pyrimidinyl-6,7,8,9- tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7- pyrimidinyl-2,3-dihydroimidazo(1,2-a)pyrimidin- 5(1h)onderivate gegen neurodegenerative erkrankungen ATE307815T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01402431A EP1295884A1 (de) 2001-09-21 2001-09-21 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on Derivate
EP02290488A EP1340760A1 (de) 2002-02-28 2002-02-28 Substituierte 2-Pyrimidinyl-6,7,8,9-tetrahydro[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
PCT/EP2002/011127 WO2003027115A1 (en) 2001-09-21 2002-09-19 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders

Publications (1)

Publication Number Publication Date
ATE307815T1 true ATE307815T1 (de) 2005-11-15

Family

ID=26077255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779461T ATE307815T1 (de) 2001-09-21 2002-09-19 Substituierte 2-pyrimidinyl-6,7,8,9- tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7- pyrimidinyl-2,3-dihydroimidazo(1,2-a)pyrimidin- 5(1h)onderivate gegen neurodegenerative erkrankungen

Country Status (23)

Country Link
US (2) US7388005B2 (de)
EP (1) EP1430056B1 (de)
JP (2) JP4570361B2 (de)
KR (1) KR100868840B1 (de)
CN (1) CN1247586C (de)
AR (1) AR036599A1 (de)
AT (1) ATE307815T1 (de)
AU (1) AU2002342798C1 (de)
BR (1) BR0212904A (de)
CA (1) CA2457952C (de)
CY (1) CY1105553T1 (de)
DE (1) DE60206946T2 (de)
DK (1) DK1430056T3 (de)
EA (2) EA009456B1 (de)
ES (1) ES2250721T3 (de)
HU (1) HUP0500332A3 (de)
IL (2) IL160397A0 (de)
MX (1) MXPA04002632A (de)
NO (1) NO329566B1 (de)
NZ (1) NZ531244A (de)
PL (1) PL370535A1 (de)
SI (1) SI1430056T1 (de)
WO (1) WO2003027115A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454909B1 (de) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one und 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one Derivate und deren Benutzung gegen neurodegenerative Krankheiten
EP1557417B1 (de) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituierte 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one Derivate
WO2005070932A2 (en) 2004-01-22 2005-08-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008543840A (ja) * 2005-06-14 2008-12-04 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (de) 2006-12-20 2008-07-02 Sanofi-Aventis Substituierte Heteroaryl-Pyridopyrimidon-Derivate
EP1992621A1 (de) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamid-substituierte Pyrimidon-Derivate zur Behandlung von neurodegenerativen Krankheiten
EP1992624A1 (de) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamid-Pyrimidon-Verbindungen
EP1992625A1 (de) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamid-Pyrimidon-Verbindungen
EP1992620A1 (de) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamid-Pyrimidon-Derivate zur Behandlung von neurodegenerativen Krankheiten
EP2085400A1 (de) * 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Heteroarylamid-Oxazepinopyrimidon-Derivate
EP2090579A1 (de) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Heteroarylamiddiazepinopyrimidon-Derivate
EP2085399A1 (de) * 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Arylamidoxazepinopyrimidon-Derivate
EP2090578A1 (de) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Arylamid-Diazepinopyrimidon-Derivate zur Behandlung von neurodegenerativen Erkrankungen verursacht durch eine abnormale GSK3-beta-Aktivität
EP2138485A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte N-Oxid-Pyrazin-Derivate
EP2138498A1 (de) * 2008-06-26 2009-12-30 sanofi-aventis Substituierte trizyklische Derivate gegen neurodegenerative Erkrankungen
EP2138493A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidon-Derivate
EP2138494A1 (de) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Alkylpyrimidin-4-one-Derivate
EP2138492A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidin-4-one-Derivate
EP2138488A1 (de) 2008-06-26 2009-12-30 sanofi-aventis 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen
EP2138495A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8421890B2 (en) 2010-01-15 2013-04-16 Picofield Technologies, Inc. Electronic imager using an impedance sensor grid array and method of making
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP7403351B2 (ja) 2020-02-27 2023-12-22 三菱重工業株式会社 通信ポイント決定装置、通信ポイント決定方法およびプログラム、並びに点検システム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
SU600143A1 (ru) * 1976-12-06 1978-03-30 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср Способ получени гетероциклических систем, содержащих бормзамещенный имидазол
JPS63216886A (ja) * 1987-03-05 1988-09-09 Sumitomo Chem Co Ltd ピリミドピリミジン誘導体およびその製造法
JP2862958B2 (ja) * 1990-06-09 1999-03-03 三協化学株式会社 感熱転写記録用色素
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
BR9908004A (pt) * 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments

Also Published As

Publication number Publication date
CY1105553T1 (el) 2010-07-28
DE60206946T2 (de) 2006-07-27
KR20040039390A (ko) 2004-05-10
EA200600196A1 (ru) 2006-08-25
EP1430056B1 (de) 2005-10-26
JP4570361B2 (ja) 2010-10-27
HUP0500332A2 (hu) 2005-07-28
JP2005504809A (ja) 2005-02-17
IL160397A0 (en) 2004-07-25
ES2250721T3 (es) 2006-04-16
US20040266793A1 (en) 2004-12-30
EP1430056A1 (de) 2004-06-23
CA2457952C (en) 2009-11-10
JP2010189422A (ja) 2010-09-02
WO2003027115A1 (en) 2003-04-03
IL160397A (en) 2009-07-20
EA007165B1 (ru) 2006-08-25
CA2457952A1 (en) 2003-04-03
HUP0500332A3 (en) 2009-12-28
US20080269257A1 (en) 2008-10-30
EA009456B1 (ru) 2007-12-28
MXPA04002632A (es) 2004-07-08
AU2002342798B2 (en) 2008-01-10
NZ531244A (en) 2006-06-30
KR100868840B1 (ko) 2008-11-14
US7388005B2 (en) 2008-06-17
CN1556810A (zh) 2004-12-22
NO329566B1 (no) 2010-11-15
EA200400236A1 (ru) 2004-10-28
SI1430056T1 (sl) 2006-02-28
BR0212904A (pt) 2004-10-13
DE60206946D1 (de) 2005-12-01
AR036599A1 (es) 2004-09-22
PL370535A1 (en) 2005-05-30
HK1091495A1 (zh) 2007-01-19
CN1247586C (zh) 2006-03-29
DK1430056T3 (da) 2006-02-27
US7781440B2 (en) 2010-08-24
NO20041142L (no) 2004-06-21
AU2002342798C1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE307815T1 (de) Substituierte 2-pyrimidinyl-6,7,8,9- tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7- pyrimidinyl-2,3-dihydroimidazo(1,2-a)pyrimidin- 5(1h)onderivate gegen neurodegenerative erkrankungen
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
DE60205921D1 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
DE60318888D1 (de) Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung
IL157640A0 (en) Pyrazolopyrimidines as therapeutic agents
ATE269333T1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
DK1608654T3 (da) 8-substituerede-6, 7, 8, 9-tetrahydropyrimido (1,2- a) pyrimidin-4-on-derivater
SI1603915T1 (sl) SUBSTITUIRANI 8-PIRIDINIL-DIHIDROSPIRO-CIKLOALKIL-PIRIMIDO 1,2-a PIRIMIDIN-6-ONSKI IN 8-PIRIMIDINIL-DIHIDROSPIRO-CIKLOALKIL-PIRIMIDO 1,2-a PIRIMIDIN-6-ONSKI DERIVATI IN NJIHOVA UPORABA PROTI NEVRODEGENERATIVNIM BOLEZNIM
DK1608653T3 (da) Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater
AU2001250376A1 (en) Dihydroimidazo(2,1-b)thiazole and dihydro-5h-thiazolo(3,2-a)pyrimidines as antidepressant agents
DE50208341D1 (de) Triazolopyrimidine
ATE326467T1 (de) Imidazo 1,2-aöpyridine
NO20031588L (no) Substituerte 3,4-dihydro-pyrimido(1,2-a)pyrimidiner og 3,4- dihydropyrazino(1,2-a)pyrimidiner
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner
TJ431B (en) 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity
AU2002325550A1 (en) (1,2,4)triazolo(1,5-a)pyrimidine derivative
HK1063050A (en) Pyrazolopyrimidines as therapeutic agents
SI1325010T1 (en) Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines
HK1084664A (en) Pyrazolo [1,5-a] pyrimidine derivatives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1430056

Country of ref document: EP